Insider Purchases: Inside the Buy
Tag: Turnaround
Dexcom’s COO Just Bought ~$1M of Stock — Sweet Signal or Just a Sugar Rush?
Dexcom’s insider buy just spiked the glucose of Wall Street chat rooms. The COO is buying big, AI features are rolling, and institutions own almost everything. Is DXCM a sweet buy or a sugar rush in disguise? 🍬📈
Two Directors Are Buying Clarivate. Should You Buy CLVT?
Two Clarivate directors just made multi-million-dollar insider buys, betting that the data-intelligence firm’s turnaround is for real. The company is paying down debt, buying back shares, and leaning hard into AI-driven analytics. But is this a deep-value opportunity — or just another corporate clarinet solo waiting to go off-key? 🎶
Insiders Had Bought Shares of Elanco Animal Health (ELAN); Turns Out They Were Right — And It May Only Be the Beginning!
Insiders bought millions of Elanco shares under $15 — and they were right. Now, with JP Morgan’s upgrade and revenues rising, this stock might be a hidden gem in the animal health world. 🐾
AngioDynamics (ANGO)’s CEO Bought Shares a Year Ago and Stock Doubled Since: Will They Keep Going Higher?
AngioDynamics insiders bought low and doubled up, while Wall Street funds practically own the company. With MedTech sales surging and earnings around the corner, can $ANGO climb higher — or will tariffs and volatility zap the gains?